Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary NeuroMetrix to Present Data on Quell Sleep Monitoring Technology at Upcoming American Academy of Neurology Annual Meeting
WALTHAM, Mass. , April 18, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported that it will present a scientific poster at the upcoming 2018 American Academy of Neurology (AAN) Annual Meeting to be held in Los Angeles, CA , April 21-27 .
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for 2018 First Quarter Financial Results Conference Call
WALTHAM, Mass. , April 11, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that it plans to issue its 2018 first quarter financial results before the opening of the market on Thursday, April 19, 2018. The Company will host a conference call at 8:00 a.m., Eastern
View HTML
Toggle Summary NeuroMetrix Reports Results of Large Clinical Study of Quell Wearable Pain Relief
WALTHAM, Mass. , April 10, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported publication of results from a clinical study of Quell® in the Journal of Pain Research .  The paper is titled “Effectiveness of fixed-site high-frequency transcutaneous electrical nerve stimulation
View HTML
Toggle Summary NeuroMetrix to Present Quell Data at 2018 American Pain Society Meeting
WALTHAM, Mass. , March 01, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) today reported that it will present a scientific poster at the upcoming 2018 American Pain Society (APS) Annual Scientific Meeting to be held in Anaheim, CA, March 4-6.
View HTML
Toggle Summary NeuroMetrix Reports Q4 and Full Year 2017 Financial Results
Q4 revenue $4.9M up 33%. Full year 2017 revenue $17.1M up 42%. WALTHAM, Mass. , Jan. 25, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported financial and business highlights for the quarter ended December 31, 2017 . The Company develops and markets novel therapies, based on
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2017 Financial Results Conference Call
WALTHAM, Mass. , Jan. 18, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (NASDAQ:NURO) announced today that it plans to issue its fourth quarter and full year 2017 financial results before the opening of the market on January 25, 2018. The Company will host a conference call at 8:00 a.m., Eastern
View HTML
Toggle Summary NeuroMetrix and GlaxoSmithKline Consumer Healthcare Announce Strategic Collaboration to Develop and Expand Access to Quell Wearable Pain Relief Technology
WALTHAM, Mass. , Jan. 17, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today a collaboration with GlaxoSmithKline (NYSE:GSK), one of the world's largest science-led global healthcare companies, involving Quell ®  Wearable Pain Relief Technology™.
View HTML
Toggle Summary NeuroMetrix Reports Preliminary 2017 Financial Highlights
WALTHAM, Mass. , Jan. 08, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported preliminary financial highlights for the fourth quarter and for the full year 2017. GAAP revenue for the fourth quarter of 2017 is estimated at approximately $4.9 million in comparison with $3.7
View HTML
Toggle Summary NeuroMetrix CEO to Participate in CES 2018 Panel on Opioid Crisis
WALTHAM, Mass. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that Shai N. Gozani M.D ., Ph.D., President and Chief Executive Officer, will participate in a panel at the Digital Health Summit at CES 2018.  The panel, “The Vicious Spiral: How Will the Opioid
View HTML
Toggle Summary NeuroMetrix to Present at Upcoming Biotech Showcase and Digital Medicine Showcase Conferences
WALTHAM, Mass. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the 10 th Annual Biotech Showcase 2018 Conference at the Hilton San Francisco Union Square on Monday,
View HTML